StockIQpro
NASDAQ:UNCY

Unicycive Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Unicycive Therapeutics, Inc. reported net income of −$26.6M in fiscal 2025. Free cash flow was −$31.3M, and the diluted share count rose 137.2%.Summary generated from Unicycive Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−141.1%
Debt / equityn/a
Free cash flow−$31.3M
FCF marginn/a
Share count change+137.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a11n/an/a
Operating income−9−18−21−32−30
Net income−10−18−31−37−27
Free cash flow−6−16−18−29−31

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations